Follow the entities shaping the evidence.

…s BRCA1, BRCA2, ATM, CHEK2, PALB2 in different murine and human breast cancer cell lines. The CRISPR engineered cells were implanted in mice …

…n while modulating immunosuppressive regulatory T cell (T reg). HM16390 is a novel, long-acting IL-2 analog engineered with precise bin…

…lizumab (1200mg Q3W) in heavily pretreated patients (n=44) with MSS mCRC, including 27 with non liver metastases (NLM). In an explorator…

…rming successful engraftment and tumor infiltration.Conclusions AGX-148 offers a novel, biomarker selection strategy enriching for tumo…

…ttps://doi.org/10.1016/j.annonc.2022.01.051Kang M, Yoo S, Ma S. BAL0891 as a dual kinase inhibitor inducing anti-tumor immunity: A prom…

…Background Neuroblastoma is the most common pediatric solid cancer, outside of brain can…

…atezolizumab both as a single treatment and in combination with BNT314. In vivo, combining mPD-L1xmVEGF-A with hEpCAMxm4-1BB delayed o…

…ed to a 4-fold reduction with the single GLP-1 receptor agonist semaglutide. Remarkably, the anti-tumor effects of RETA persisted after tre…

…ghlighting FASN as a therapeutic target to sensitize irradiated glioblastoma to immunotherapy.Ethics Approval Animal studies were approved b…

…ment (TME). 1 Therefore, we propose a combination approach with [67Cu]Cu-LLP2A, a radiopharmaceutical therapy (RPT) targeting the very late an…

…Background Breast cancer remains the most commonly diagnosed cancer among women in the U…

…ysis of long-term survival data from phase II and III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(1…